Cyclerion Therapeutics, Inc. (CYCN) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
CYCN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CYCN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -239.8% | -170.1% |
| 2024 | 100.0% | -181.4% | -152.8% |
| 2023 | - | - | - |
| 2022 | -1778.5% | -6242.4% | -14841.1% |
| 2021 | 100.0% | -1662.5% | -1555.6% |
Download Data
Export CYCN earnings history in CSV or JSON format
Free sign-in required to download data
Cyclerion Therapeutics, Inc. (CYCN) Earnings Overview
As of May 8, 2026, Cyclerion Therapeutics, Inc. (CYCN) reported trailing twelve-month net income of -$4M, reflecting +9.9% year-over-year growth. The company earned $-1.09 per diluted share over the past four quarters, with a net profit margin of -170.1%.
Looking at the long-term picture, CYCN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2024.
Cyclerion Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ADMA ($165M net income, 28.8% margin), IMVT (-$464M net income), KALA (-$36M net income), CYCN has room to improve margins relative to the peer group. Compare CYCN vs ADMA →
CYCN Earnings vs Peers
Earnings metrics vs comparable public companies
CYCN Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$4M | -15.4% | -$5M | $-1.09 | -170.1% | -239.8% |
| 2024 | -$3M | +41.9% | -$4M | $-1.21 | -152.8% | -181.4% |
| 2023 | -$5M | +88.1% | -$13M | $-8.99 | - | - |
| 2022 | -$44M | +14.7% | -$19M | $-20.15 | -14841.1% | -6242.4% |
| 2021 | -$52M | +33.6% | -$55M | $-26.40 | -1555.6% | -1662.5% |
| 2020 | -$78M | +36.8% | -$81M | $-47.80 | -3388.6% | -3539.4% |
| 2019 | -$123M | -6.7% | -$125M | $-88.37 | -2729.3% | -2774.3% |
| 2018 | -$115M | -22.7% | -$115M | $-84.42 | - | - |
| 2017 | -$94M | - | -$94M | $-68.80 | - | - |
See CYCN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CYCN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CYCN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCYCN — Frequently Asked Questions
Quick answers to the most common questions about buying CYCN stock.
Is CYCN growing earnings?
CYCN EPS stands at $-1.09, with +9.9% growth matching the 5-year CAGR of N/A. TTM net income is $-4M. Earnings trajectory remains consistent.
What are CYCN's profit margins?
Cyclerion Therapeutics, Inc. net margin is -170.1%, with operating margin at -239.8%. Below-average margins reflect competitive or cost pressures.
How consistent are CYCN's earnings?
CYCN earnings data spans 2017-2025. The current earnings trend is +9.9% YoY. Historical data enables comparison across business cycles.